Crispr Therapeutics (NASDAQ:CRSP) had its price objective hoisted by analysts at Roth Capital from $50.00 to $65.00 in a research report issued on Tuesday, The Fly reports. Roth Capital’s price objective indicates a potential upside of 28.15% from the company’s previous close.

Several other analysts have also issued reports on the stock. Barclays upped their price target on shares of Varonis Systems from $71.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday. William Blair reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday. Canaccord Genuity set a $37.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research report on Friday. BidaskClub lowered shares of YRC Worldwide from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Finally, Chardan Capital set a $73.00 price target on shares of Crispr Therapeutics and gave the stock a “buy” rating in a research report on Friday, June 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $57.40.

NASDAQ CRSP traded down $0.60 on Tuesday, hitting $50.72. 831,861 shares of the stock were exchanged, compared to its average volume of 658,238. The company has a debt-to-equity ratio of 0.08, a current ratio of 15.84 and a quick ratio of 15.84. The business has a fifty day simple moving average of $47.46. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $59.00. The stock has a market capitalization of $2.75 billion, a P/E ratio of -14.74 and a beta of 3.11.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, July 29th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.84). Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. During the same period last year, the company posted ($0.82) earnings per share. The business’s revenue was down 70.8% compared to the same quarter last year. On average, equities analysts expect that Crispr Therapeutics will post -3.7 EPS for the current fiscal year.

In related news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $46.00, for a total value of $920,000.00. Following the transaction, the chief executive officer now directly owns 185,801 shares in the company, valued at $8,546,846. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 50,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $45.00, for a total transaction of $2,250,000.00. Following the completion of the transaction, the president now owns 898,007 shares in the company, valued at $40,410,315. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,000 shares of company stock worth $6,670,400. Corporate insiders own 21.40% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC grew its stake in shares of Crispr Therapeutics by 71.4% in the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after acquiring an additional 302 shares in the last quarter. BNP Paribas Arbitrage SA acquired a new position in shares of Crispr Therapeutics in the second quarter valued at about $41,000. Lenox Wealth Management Inc. grew its stake in shares of Crispr Therapeutics by 1,731.7% in the first quarter. Lenox Wealth Management Inc. now owns 2,198 shares of the company’s stock valued at $79,000 after acquiring an additional 2,078 shares in the last quarter. Dubuque Bank & Trust Co. grew its stake in shares of Crispr Therapeutics by 101.6% in the first quarter. Dubuque Bank & Trust Co. now owns 2,873 shares of the company’s stock valued at $103,000 after acquiring an additional 1,448 shares in the last quarter. Finally, Flagship Harbor Advisors LLC grew its stake in shares of Crispr Therapeutics by 22.1% in the first quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock valued at $118,000 after acquiring an additional 600 shares in the last quarter. Institutional investors and hedge funds own 48.92% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What is an SEC Filing?

The Fly

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.